Get 40% Off
💰 Warren Buffett reveals a $6.72 billion stake in ChubbCopy Portfolios

Wall Street advances on positive start to earnings, vaccine hopes

Published 07/13/2020, 07:00 AM
Updated 07/13/2020, 12:00 PM
© Reuters. The spread of the coronavirus disease (COVID-19) in New York
US500
-
DJI
-
GILD
-
ADI
-
PFE
-
PEP
-
MXIM
-
TSLA
-
IXIC
-
SOX
-
SPXHC
-
SPLRCD
-
SPLRCT
-
BNTX
-

By Medha Singh and Devik Jain

(Reuters) - Wall Street's main indexes rose on Monday with the Nasdaq at a fresh intraday record high as investors cheered signs of progress in COVID-19 vaccine development and an upbeat start to the second-quarter earnings season by PepsiCo.

Shares of German biotech firm BioNTech (O:BNTX) jumped 19.6% and Pfizer Inc (N:PFE) climbed 4.2% as two of their experimental coronavirus vaccines received the U.S. FDA's "fast track" designation.

"It's selective optimism as we enter earnings season, chasing the same stocks that have been strong and looking forward to earnings as market continues to have a narrow focus," said Andre Bakhos, managing director at New Vines Capital LLC in Bernardsville, New Jersey.

Merger news also perked up investors as Analog Devices Inc (O:ADI) announced a $21 billion deal to buy rival Maxim Integrated Products Inc (O:MXIM), whose shares rose 11.4%. Analog shares fell 3.4%.

The Philadelphia SE Semiconductor index (SOX) rose 1.8%.

PepsiCo Inc (O:PEP) gained 2.2% as it benefited from a surge in at-home consumption of salty snacks such as Fritos and Cheetos during lockdowns.

Investors are bracing for what could be the sharpest drop in quarterly earnings for S&P 500 firms since the financial crisis, according to IBES Refinitiv data. Results from big banks will be in focus this week.

The April-June reports will reveal the extent of the damage wreaked by coronavirus-induced lockdowns on corporate profits. With a record jump in cases in the United States and some other hotspots around the world, analysts have predicted a return to S&P 500 earnings growth only by 2021. (Graphic: S&P 500 versus financials: widest gap since GFC, https://fingfx.thomsonreuters.com/gfx/mkt/jbyvrrwjave/SPX%20versus%20financials.png)

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Fatality rates from the coronavirus are holding reasonably stable, allowing markets to look beyond the increase in new cases and toward continued improvement in economic data and the recovery going forward, said Michael Arone, chief investment strategist at State Street (NYSE:STT) Global Advisors in Boston.

The S&P 500 is about 5% below its own record high hit in February. At 11:15 a.m. ET, the Dow Jones Industrial Average (DJI) was up 399.92 points, or 1.53%, at 26,475.22, the S&P 500 (SPX) was up 41.46 points, or 1.30%, at 3,226.50. The Nasdaq Composite (IXIC) was up 187.18 points, or 1.76%, at 10,804.62.

Technology (SPLRCT), healthcare (SPXHC) and consumer discretionary (SPLRCD) rose the most among the 11 major S&P sectors.

Tesla Inc (O:TSLA) jumped 14.4% to $1,767.26, building on a rally of nearly 25% in the past two consecutive weeks. Over the weekend, it slashed the price for its Model Y SUV.

Advancing issues outnumbered decliners by a 1.94-to-1 ratio on the NYSE and by a 1.26-to-1 ratio on the Nasdaq.

The S&P index recorded 38 new 52-week highs and no new low, while the Nasdaq recorded 111 new highs and 12 new lows.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.